Physiomics PLC - mathematical modelling company that supports oncology drug development - Wins further contract from existing client Numab Therapeutics AG. Says the project involves pharmacokinetic-pharmacodynamic modelling in support of one of Numab's oncology assets entering the clinic and will help inform dose and scheduling decisions. Chief Executive Officer Peter Sargent comments: "We are thrilled to have this opportunity to continue working with and supporting Numab on this asset through its preclinical stages as it heads into the clinic. Along with the project we announced with them in August 2023, this new project is testament to the continued support we provide and the great relationships we've built."
Current stock price: 1.50 pence, down 3.5%
12-month change: down 64%
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Physiomics (PYC)